Glycogen synthase kinase-3β (GSK-3β), a serine/threonine protein kinase, has been reported to show essential roles in molecular pathophysiology of many diseases. Mitochondrion is a dynamic organelle for producing cellular energy and determining cell fates. Stress-induced translocated GSK-3β may interact with mitochondrial proteins, including PI3K-Akt, PGC-1α, HK II, PKCε, components of respiratory chain, and subunits of mPTP. Mitochondrial pool of GSK-3β has been implicated in mediation of mitochondrial functions. GSK-3β exhibits the regulatory effects on mitochondrial biogenesis, mitochondrial bioenergetics, mitochondrial permeability, mitochondrial motility, and mitochondrial apoptosis. The versatile functions of GSK-3β might be associated with its wide range of substrates. Accumulative evidence demonstrates that GSK-3β inactivation may be potentially developed as the promising strategy in management of many diseases, such as Alzheimer's disease (AD) and Parkinson's disease (PD). Intensive efforts have been made for exploring GSK-3β inhibitors. Natural products provide us a great source for screening new lead compounds in inactivation of GSK-3β. The key roles of GSK-3β in mediation of mitochondrial functions are discussed in this review.
Introduction
GSK-3 has two isoforms α and β, which have similar biological functions. Most of GSK-3β locates in the cytoplasm, and small amounts can be detected in the mitochondria and in the nucleus. But GSK-3α is not detectable in the mitochondria [1] . It has been demonstrated that the constitutive activity of GSK-3β in the mitochondria and nuclei is much higher for 5-8 folds than that in the cytoplasm in SH-SY5Y cells [2] . In normal myocardium, phosphor-Ser9-GSK-3β predominantly locates in the cytosol. In contrast, under stressful conditions, such as
The structure and biology of GSK-3β
The two mammalian GSK-3 isoforms: α and β have 97% similarity in sequence. The crystal structure of GSK-3β (Fig. 1A) shows two domain kinase folds: a β-strand domain formed by residues 25-138 at N-terminus and an α-helical domain formed by residues 139-343 at Cterminus. However, the structure of residues 7-24 is invisible, due to no electron density [7] . These residues form a loop to bring phosphor-Ser9 in contact with the basic residues and subsequently prevent against binding a substrate in the groove. The ATP-binding domain locates at the interface of β-strand and α-helical domain. The activation loop ranges from residue 200 to residue 226, running along the groove surface for binding the substrates [8] . This activation loop (Fig. 1B) is well orchestrated to position against the α-helical domain. This orientation prepares an available groove for binding a substrate. Thus, phosphorylation of Tyr216 increases the enzymatic activity of GSK-3β. The protein structure indicates that GSK-3β favors to phosphorylate at P site in a substrate with SXXXS motif, which has been first phosphorylated at the [P+4] serine position. Substrates, such as adenomatous polyposis coli protein (APC), eukaryotic initiation fact 2b (eIF2b), and GS, are phosphorylated by GSK-3β in the similar manner [9] . However, not all substrates are phosphorylated with the same style/efficiency. Tau, β-catenin, and Axin are phosphorylated without requiring a prior phosphorylation at [P+4] serine position. But the phosphorylation efficiency of GSK-3β can increase 50 folds, if phophoserine at [P+4] position is introduced firstly [9] .
Structural modification is closely related to biological function alternations. GSK-3β is a substrate of many signaling pathways, including PI3K/ Akt and insulin. Inhibitory phosphorylation at Ser9 inactivates GSK-3β through Akt signaling, which is also the mechanism for insulin to activate glycogen synthase (GS) [10] . GSK-3β has been originally identified as a modulator of glycogen metabolism, and now it is known to regulate various signaling pathways controlling cell fates. 
GSK-3β regulates mitochondrial biogenesis
The location of GSK-3β in the mitochondria indicates that there are accessible substrates existing in this organelle and regulating mitochondrial metabolism. Increased mass of mitochondrial DNA is often considered as an indication of enhancement in mitochondrial biogenesis. PGC-1α and mitochondrial transcription factor A (mtTFA) are often used as the markers for evaluating mitochondrial biogenesis. LiCl, a GSK-3β inhibitor, has been demonstrated to exhibit mitochondrial biogenesis by the possible mechanism that LiCl significantly up regulate the expression of PGC-1α and mtTFA with increase in DNA content in mitochondria, leading to maturation of megakaryocytes [11] .
In C2C12 myotubes, insulin promotes the genes expression of mitofusin 2 protein (Mfn2), mtTFA, mitochondrial single-stranded DNA-binding protein (MtSSB), and nuclear encoded cytochrome c oxidase subunit IV (COX IV), which are the critical factors regulating mitochondrial functions. It has been demonstrated that insulin-dependent mitochondrial biogenesis is regulated by PI3K/Akt signaling through inhibition of GSK-3β [12] . Forkhead box protein O1 (FOXO1) promotes the expression of the downstream factor PGC-1α [13] . However, the activity of PGC-1α can be repressed by phosphorylated FOXO1 [14] . Insulin reduces the activity of FOXO1 and alters the phosphorylation status of GSK-3β in a PI3K/ Akt signaling-dependent manner. Interestingly, GSK-3β inhibitor LiCl but not SB216763 promotes mitochondrial metabolism activity, including upregulation of Mfn-2 and COX IV expression [12] . Although GSK-3β, FOXO1, and PGC-1α are the three major Akt substrates in mediating glucose metabolism [15] , they interact with each other indirectly. GSK-3β may phosphorylate and degrade IRS-1, which acts as an upstream factor of FOXO1. It has been demonstrated that only suppression of Akt/FOXO1 signaling induces insulin resistance. In contrast, PGC-1α-S570A or GSK-3β-S9A does not have any effects on insulin sensitivity [15] .
It has been shown that GSK-3β acts as a substrate and cleaved by Omi, which is a serine protease mainly in mitochondria and plays a critical role in maintaining the integrity of mitochondria [16] . Omi deficiency causes decreased number of mitochondria, reduced electron density, and decreased expression of mitochondrial components, including COX IV, COX II, Cyt c, and ANT1. These are associated with down-regulation of PGC-1α, which is negatively mediated by GSK-3β through affecting the interaction of SCF-Cdc4 E3 ligase complex with PGC-1α. However, the detailed mechanism is still under investigation [4] . Consistently, glucagon-like peptide-1 (GLP-1) and exendin-4 (EX-4) have been shown to promote mitochondrial biogenesis and the expression of anti-oxidants through upregulation of PGC-1α activity and down-regulation of GSK-3β activity in advanced glycation end products (AGEs)-induced AD. Further, immunoprecipitation assays show that PGC-1α may physically bind to GSK-3β, which is inactivated by phosphorylation at Ser9 induced by GLP-1/Ex-4 in vivo and in vitro. However, deficiency of GLP-1/Ex-4 impairs the association between PGC-1α and GSK-3β [17] .
Histone H2A variant X (H2AX) locates in both nuclei and mitochondria, and it has been demonstrated that H2AX plays a key role in mitochondrial DNA repair and stability. H2AX deficiency exhibits mitochondrial defects with alternations in morphology and genes expression. In nuclei, H2AX directly binds to DNA for repairing activity. In contrast, in mitochondrial H2AX directly binds to not DNA but TOM20, a component of import machinery in outer membrane of mitochondria, for transporting mitochondrial precursor proteins into the mitochondria [18] . It has been demonstrated that the phosphorylation of histone H2AX-Ser139 to form γH2AX. Akt is the downstream factor and phosphorylated at Thr-308 and Ser-473 by DNA-dependent protein kinase complex (DNA-PKcs) in response to DNA damage. DNA-PKcs directly promotes H2AX phosphorylation and stabilizes γH2AX, and GSK-3β inactivation prolongs the time of γH2AX elevation [19] . Co-immunoprecipitation assays show that GSK-3β and TOM20 are both new substrates of E3 ligase SCF Fbxo7 using a high-throughput, cell-independent proteomic approach. SCF Fbxo7 ubiquitinates GSK-3β in a K63-dependent manner and Fbxo7 represses its activity. In contrast, Fbxo7 stabilizes TOM20 and correlates with its levels [20] . These indicate a connective network that is a novel field for further investigation.
Conversely, it has been demonstrated that GSK-3β inactivation-induced mitochondrial ROS impair chondrocytes proliferation, leading to cell senescence, as indicated by increased expression of p21, increased activity of senescence associated β-galactosidase (SA-βGal), and cell cycle arrest at S phase in chondrocytes. This is also partially related to DNA damage, as shown by increased expression of two markers proteins γH2AX and GADD45β (growth arrest and DNA damage-inducible protein 45β). In addition, LiCl induces the protein expression of IKKα, which is correlated with the activity of GADD45β [21] . Consistently, GSK-3β inactivation is also reported to induce cellular senescence, accompanied by mitochondrial dysfunction [22] . More investigation is needed for further clear elucidation.
GSK-3β regulates mitochondrial motility
The production of mitochondrial biogenesis is often associated with fission and fusion processes, maintaining optimum functions and health. Prevention of excessive mitochondrial fission is crucial for mitochondrial quality control. Mitochondrial fusion tends to help for functional mitochondria maintenance. The mitochondrial dynamic proteins, including DLP1, Mfn1, Mfn2, MFF, Fis1, and OPA1, regulate mitochondrial fission and fusion [23] . It has been demonstrated that inhibition of p38 MAPK and GSK-3β down-regulates the expression of DLP1 and MFF and reduces mitochondrial fragmentation in cerebral ischemic injury [24] . MAP1B plays a key role in mitochondrial motility through modulation of the stability and dynamics of microtubules. Phosphorylated MAP1B by GSK-3β has been demonstrated to actively bind to microtubule and regulate its dynamics [25] .
GSK-3β has been reported to phosphorylate dynein intermediate chain (IC) at S87/ T88 in IC-1B and S88/T89 in IC-2C, which are the key sites for NDEL1 binding domain, leading to reduction of its interacting with NDEL1 [26] . Thus, the interaction of NDEL1 and dynein is negatively regulated by GSK-3β. GSK-3β inhibition may promote dynein motility. Insulin, functions for GSK-3β inhibition, promotes dynein-dependent transport in intestinal cells [27] . HDAC6 also plays an important role in mitochondrial trafficking. It has been demonstrated that inhibition of HDAC6 by tubacin significantly increases mitochondrial motility in hippocampal neurons. GSK-3β potentially binds to and phosphorylates HDAC6 at Ser22 residue, resulting in activation of HDAC6 and attenuation of mitochondrial transport [28] . Serotonin (5-HT) modulates the redistribution of energy sources, which indicates regulation of directional mitochondrial movement. It has been found that activation of 5-HT1A receptor regulates mitochondrial movement through activation of Akt/GSK-3β signaling in hippocampal neurons [29] .
Endoplasmic reticulum (ER)-mitochondria interactions are associated with axonal transport. VAPB is an ER protein with N terminus stretching into the cytoplasm. PTPIP51 is anchored in the MOM with C terminus stretching into the cytoplasm. It has been demonstrated that the segments of both VAPB and PTPIP51 interact with each other, maintaining Ca 2+ homeostasis and regulating ER-mitochondria interactions. Overexpression of GSK-3β attenuates VAPB-PTPIP51 interaction [30] . The disruption of GSK-3β-dependent VAPB-PTPIP51 interaction has been implicated in amyotrophic lateral sclerosis and frontotemporal dementia (ALS/FTD), which is accompanied by calcium homeostatic imbalance and impairment of ATP production in mitochondria [31] . The biological role of GSK-3β is still controversial. More investigation is still needed.
Mitochondrial trafficking dysfunction has been involved in the pathology of neurodegenerative diseases, including AD and PD. GSK-3β has been implicated in mediation of mitochondrial transport. TRAK1 is a key protein connecting the MOM protein Miro to the molecular motors kinesin and dynein [32] . Inconsistently, GSK-3β has been reported to be required for normal functions of motor proteins kinesin and dynein [33] . GSK-3β physically binds to TRAK1, together with DISC1 and NDE1, to form a complex, promoting mitochondrial trafficking in cultured hippocampal neurons [34] . Overexpression of GSK-3β significantly increases motile mitochondria in a Tau protein-dependent manner. However, GSK-3β does not alter mitochondrial velocity or mitochondrial run length [35] . The possible mechanism might be associated the competitive binding of Tau to microtubules with the motor proteins kinesin and dynein in a concentration-dependent manner in neurons [36] .
GSK-3β regulates mitochondrial bioenergetics
Mitochondrial volume homeostasis is important for its functions, which have been mainly implicated in energy production. GSK-3β is involved in modulating the activity of the respiratory chain. Mitochondrial normal endogenous GSK-3β alone is reported not to alter the activity of complex I. However, it is conceivable that upregulation of GSK-3β activity is correlated to suppression of complex I induced by the specific inhibitors rotenone and 1-methyl-4-phenylpyridinium ion (MPP+), leading to reduction of ATP production and activation of caspase-3-dependent apoptosis. GSK-3β-induced malfunction of complex I promotes ROS production, which can be completely abrogated by GSK-3β inhibitor LiCl or inhibitor II (Fig. 2) [37] . GSK-3β has been involved in mitochondrial ROS production. Rieske is a subunit of complex III. The deficiency of Rieske abrogates the enzymatic activity of complex III but does not affect other subunits assembly. Rieske knockout also decreases the protein levels of complex I and IV [38] . Antimycin-A (AA) triggers generation of ROS through interacting with the Qi site of the cytochrome bc1 complex in complex III, resulting in inhibiting the activity of complex III. It has been demonstrated that AA-promoted interaction between GSK-3β and Rieske is associated with ROS production in H9c2 and C2C12 cells [39] . mK ATP channel activators can promote the inhibitory phosphorylation of GSK-3β, attenuate the interaction of GSK-3β-Rieske, and decrease ROS generation. GSK-3β inactivation plays a critical role in mediating the activities of complex I, II, III, and IV, which are negatively affected by bupivacaine (Fig. 2) . Lipid emulsion (LE) exhibits the cardioprotective activity against the cytotoxicity of bupivacaine in H9c2 cells through Akt/GSK-3β signaling pathway [40] .
Complex IV in mitochondrial respiratory chain is the final electron acceptor to transfer the electron to an oxygen molecule, generating H 2 O. This complex is the only one not to produce superoxide in mitochondria. However, it is reported that the mitochondrial superoxide can be induced through modulation of the complex IV activity [41] . The subunit 6b of complex IV shows high binding affinity to mitochondrial GSK-3β, which in turn phosphorylates subunit 6b in complex IV. In Mv1Lu cells, TGFβ1 induces cell senescence via promotion of mitochondrial ROS production. GSK-3β is a downstream factor of TGFβ1 signaling [42] . Inactivation of GSK-3β with phosphorylation at Ser9 is implicated in TGFβ1-induced cell senescence, which might be association of disruption of complex IV activity [43] . GSK-3β inactivation by LiCl can be a result of activation of PI3K-Akt signaling, which is recently reported to be linked to activation of enzymes in NADPH oxidase family, leading to enhancement of ROS production [44] . GSK-3β has been known to inhibit the activity of glycogen synthase. LiCl treatment or GSK-3β inactivation can induce increased glycogenesis, which might be associated with cellular senescence and aging [45] .
Pyruvate dehydrogenase (PDH) converts pyruvate to acetyl CoA in mitochondria and plays an essential role in glycolytic pathway and tricarboxylic acid cycle (TCA). PDH has been demonstrated to be the substrate for TPKI/GSK-3β, which predominantly locate in mitochondria. Activated TPKI/GSK-3β is shown to phosphorylate and suppress PDH, leading to disruption of glucose metabolism [46] . Similar results are obtained in DU145 and PC3 cells [47] . Cardiolipin is an important mitochondrial phospholipid, which is essential for the electron transport chain and ATP production. It has been demonstrated that cardiolipid synthase knockdown significantly decrease the capacity of spare respiration, but does not affect the activity of complex I in hCMEC/D3 cells. The possible compensatory Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry mechanism might be associated with increased utilization of glucose, as shown by increased glycolysis and increased activity of pyruvate kinase and GLUT1, which are correlated with inactivation of GSK-3β [48] . GSK-3β inactivation or GSK-3β-Ser9 phosphorylation maintains the efficiency of oxidative phosphorylation (OXPHOS) and controls the production of ROS. Ischemic preconditioning (IPC) promotes the concentration of phospho-Ser9-GSK-3β in mitochondria, which directly binds to adenine nucleotide translocator (ANT), resulting in modulation of mitochondrial permeability transition (MPT) functions [49] .
GSK-3β regulates mitochondrial permeability
mPTP, locates in the inner mitochondrial membrane, plays a critical role in cell death. In normal cells, mPTP is closed. mPTP is triggered and opened under stressful conditions, including oxidative stress, Ca 2+ overload, increased phosphate concentration, and adenine nucleotide deficiency [50] . Three key components, including ANT, cyclophilin D (CyP-D), and voltage-dependent anion channel (VDAC) form mPTP, which is opened by the binding of CyP-D to ANT [51] . Once opened, any molecule less than 1500 Da can pass through mPTP into mitochondria, leading to the swelling of matrix, disruption of mitochondrial membrane potential (ΔΨ m ), and ATP depletion. CyP-D-ANT interaction decreases the threshold of mPTP in sensitizing Ca
2+
. Suppression of CyP-D-ANT interaction contributes to attenuation of mPTP opening (Fig. 2) .
The dysregulation of mPTP might be the downstream effects of GSK-3β directly or indirectly. This indicates that phosphor-Ser9-GSK-3β is positively correlated with mPTP opening threshold. Specifically, GSK-3β inhibition decreases the binding of CyP-D to ANT, which interaction can significantly reduce the opening threshold of mPTP (Fig.  2) [6]. Phosphor-Ser9-GSK-3β has been demonstrated to physically interact with ANT [52] . GSK-3β is a key factor in Wnt signaling, which has been reported to regulate the activity of mPTP [53] . Bcl-2 is the target gene of Wnt signaling to participate in the stabilization of mitochondria against Aβ damage. The possible mechanism might be associated with binding of Bcl-2 to CyP-D [54] . There are three isoforms (VDAC1, VDAC2, and VDAC3) in the mitochondrial outer membrane (MOM), regulating metabolic exchange across MOM. VDAC2, but not VDAC1 or VDAC3, has been reported to physically bind to BAK in the MOM. Under stress, the BH3-only proteins such as BIM, BAD, or tBID compete and displace VDAC2 from BAK, initiating cell apoptosis [55] . It has been demonstrated that GSK-3β inhibition delays the opening of mPTP in response to oxidative stress through dephosphorylation of VDAC. This could be associated with reduction of mitochondrial calcium loading, which is forced by ΔΨ m [56] . Further studies show that GSK-3β physically interacts with VDAC2 through its N-terminal domain under oxidative stress. Selective knockdown of VDAC2 or kinase-deficiency GSK-3β K15A mutant can significantly suppress the translocation of GSK-3β and mPTP opening in H9c2 cardiomyoblasts [57] . This indicates that mediation of mPTP opening by GSK-3β is VDAC2-and kinase-dependent. In addition, GSK-3β inhibition also promotes the binding affinity of Bcl-2 to mitochondrial VDAC, due to alternation of phosphorylation of VDAC [58] .
Hexokinase II (HK-II), existed in MOM, has been reported to be another important mediator for mPTP. Detachment of HK-II from mitochondria may induce mPTP opening and subsequent cell apoptosis. Akt phosphorylates HK-II and promotes it to bind to mitochondria. GSK-3β activation may induce HK-II release from mitochondria, initiating mitochondria-dependent apoptosis (Fig. 2) [59] . HK-II has been demonstrated to mainly dock with VDAC1 at mitochondria [60] . Bax mitochondrial accumulation is positively related to mitochondrial dysfunction and mitochondria-dependent apoptosis. HK-II has been demonstrated to significantly reduce the accumulation of Bax in the mitochondria under metabolic stress [61] . GSK-3β phosphorylates VDAC1 and subsequently promotes it to interact with Bax, resulting in disruption of HK-II and VDAC1 interaction [60] . Furthermore, GSK-3β might be involved in regulation of HK-II mRNA expression induced by benzo [a] pyrene [62] . CyP-D locates in the mitochondrial inner membrane. Deletion of CyP-D has been shown to exhibit significant resistance to oxidative stress and calcium overload [63] . It has been demonstrated that CyP-D is also a phosphorylatable substrate of GSK-3β through directly targeting S38, S39, and S123 residues in CyP-D (Fig. 2) . The complex GSK-3β-CyP-D facilitates mPTP opening in osteosarcoma SAOS-2 cells [64] . This also provides the evidence of GSK-3β translocation from the cytoplasm to mitochondrion through interacting with VDAC2 and CyP-D [57, 64] . Recently, CyP-D-F 1 F 0 ATP synthase interaction has been proposed to be involved in mPTP opening in diabetic mice. Blockade of such interaction provides a novel therapeutic intervention for improving synaptic plasticity, learning, and memory in diabetes [65] . P53 interacts with CyP-D and synergistically regulates the activity of mPTP. The interaction of CyP-D and p53 dictates loss of ΔΨ m , release of cytochrome c, and activation of apoptosis [66] . GSK-3β with N-terminal 78-92 residues can bind to the C-terminal domain of p53. The phosphorylation of p53 by GSK-3β is essential for its acetylation and subsequent translocation into mitochondria [67] . It has been demonstrated that p53-regulated mPTP opening can be abrogated by GSK-3β inhibition [68] .
GSK-3β regulates mitochondria-dependent apoptosis
GSK-3β has been involved in stress-induced cellular apoptosis. Activated GSK-3β can phosphorylate the downstream substrates, such as p53, Bax, and p21
Cip1
, which are important for determining cell fate. GSK-3β activation is prior to initiation of the caspase cascade correlating to cell apoptosis [69] . GSK-3β is phosphorylated and negatively regulated by many signaling pathways, including PI3K/Akt, PKA, ERK, PKC, p90rsk, and p70S6K, which
are involved in mediation of mitochondrial activity [70, 71] . GSK-3β is correlated with activation of caspase-2 and caspase-8, which can induce the cleavage of Bid and the release of cytochrome c, leading to mitochondrial dysfunction and apoptosis. It has been demonstrated that inhibitory phosphorylation of GSK-3β-Ser9 attenuates ceramide-induced mitochondrial apoptosis through inactivating caspase-2 and caspase-8 [72, 73] . Mcl-1, an anti-apoptotic member of Bcl-2 family, stabilizes mitochondrial outer membrane permeabilization through sequestering Bak-or Bax-activating proteins Bim and Bid. Mcl-1 can be phosphorylated at S159 by GSK-3β and recognized for ubiquination and degradation [74, 75] . Sarco/endoplasmic reticulum (SR/ER) is also a key player during cell death. It has been found that GSK-3β is also located in mitochondria-associated ER membrane (MAMs) and SR/ER, physically associating with IP3Rs Ca 2+ channeling. Inhibition of GSK-3β significantly reduces the formation of complex and impairs SR/ER calcium release into mitochondria at reperfusion in cardiomyocytes, leading to amelioration of calcium overload in mitochondria and subsequent cell apoptosis [76] . However, RyR-related calcium release is not affected by GSK-3β, and GSK-3β inhibition does not modify calcium-induced ΔΨ m [76] . Homeostasis of ΔΨ m is important for cell viability. Loss of ΔΨ m induced by dysregulation of mPTP leads to disruption of ATP synthesis, morphological swellness, and initiation of cell apoptosis in mitochondria. It has been demonstrated that inactivation of GSK-3β facilitates the recovery of ΔΨ m partially and exhibits cytoprotective activity in H9c2 and C2C12 cells through activation of mK ATP channel, which is ATP-dependent [39] .
Oxidative stress is also involved in mPTP opening. NF-E2-related factor (Nrf2), a master regulator of antioxidant response, is negatively regulated by GSK-3β. GSK-3β inactivation and Nrf2 upregulation by salidroside have been reported to inhibit mPTP opening, leading to decrease of ROS production, suppression of cytochrome c release, and inhibition of caspase activation [77] . Oxidative stress-induced mPTP opening can be reversed dose-dependently by tauroursodeoxycholic acid (TUDCA), an ER stress inhibitor, through activation of PI3K-Akt-GSK-3β signaling, resulting in cardioprotection against I/R injury and cell death [78] .
However, the pro-apoptotic activity of GSK-3β is controversial. GSK-3β is also required for cell survival through mediating NF-κB signaling. GSK-3β knockout mouse embryos can't survive, due to severe liver degeneration induced primarily by cellular apoptosis [10] . In addition, GSK-3β may mediate cellular growth and differentiation [79] . This might be associated with its broad range of substrates. Further efforts are needed for clear elucidation.
Natural compounds regulate mitochondrial activity through GSK-3β
Natural compounds are featured as their structural diversity and being a good source for exploring lead compounds for the potential therapeutics in modulating the activity of GSK-3β (Table 1) . Curcumin, a natural versatile compound from Curcuma longa, has been shown to improve the mitochondrial functions, decrease mitochondrial oxidative stress, and prevent cell apoptosis through activation of Akt/GSK-3β signaling in Saos-2 cells [80] . Resveratrol, the most famous polyphenol, significantly alleviates MPP+-induced mitochondrial dysfunctions through activation of Akt-GSK-3β signaling in SN4741 cells [81] . Proanthocyanidins, an effective free radical scavenger, ameliorates anoxia-reoxygenation injury through activation of PI3K-Akt-GSK-3β signaling pathway and mK ATP channel pathway in myocardial cells [82] . Asiatic acid, a pentacyclic triterpenoid isolated from Centella asiatica, exhibits protective effects against myocardial I/R injury, as indicated by improved mitochondrial functions through Akt-GSK-3β-HIF-1α signaling in hypoxic H9c2 cells [83] .
Triptolide has been shown to potentially exhibit anti-inflammatory and autoimmunesuppressive activities, accompanied by severe toxicities, such as cardiac and liver damage [84] . It has been demonstrated that selective inhibition of GSK-3β by SB216763 may significantly ameliorate the adverse effects of triptolide in H9c2 cells through inhibition of CyP-D phosphorylation and modulation of Bcl-2 family proteins, leading to desensitization of mPTP and prevention of mitochondrial apoptosis [85] . Formononetin, a natural isoflavone from Radix Astragali, has been reported to activate Akt/GSK-3β signaling in H9c2 cells. Formononetin also promotes the binding of phosphor-Ser9-GSK-3β of ANT and disruption of the complex formation of CyP-D-ANT, leading to abolishment of mPTP opening and reduction of ROS generation [86] . Hesperidin (a flavanone glycoside) has been reported to improve the deficits of learning and memory, upregulate the capacity of anti-oxidant system, and enhance the enzyme activities of mitochondrial complex I-IV through inhibition of GSK-3β activity [87] . Similarly, liquiritin, a main component of Glycyrrhiza Radix, also alleviates mitochondrial apoptotic alternations induced by glutamate predominantly through activation of ERK and Akt-GSK-3β signaling pathways [88] . Neurotoxin 6-hydroxydopamine (6-OHDA) induces initiation of mitochondria-regulated apoptotic cascade events in SH-SY5Y cells, which can be ameliorated by the administration of sulfuretin through inhibition of GSK-3β signaling and inactivation of NF-κB signaling [89] . Baicalein, isolated from Scutellaria baicalensis Georgi, increases mitochondrial phosphorylation of Akt-Thr308 and GSK-3β-Ser9, resulting in prevention of cytochrome c release in primary cultured chick cardiomyocytes [90] .
Clinical prospective
Currently, LiCl have been employed for treating Alzheimer disease. Valproic acid exhibits to promote hair growth through inhibition of GSK-3β activity and stabilization of β-catenin [91] . In addition, enzastaurin (LY317615) has been developed as an inhibitor of PKCβ to reduce GSK-3β activity through inhibiting GSK-3β phosphorylation at phase I and II in clinical tests [92] . Accumulative evidences indicate that GSK-3β has been implicated in mitochondrial functions. Rosuvastatin postconditioning exhibits protective effects against myocardial ischemia-reperfusion injury through induction of Akt and GSK-3β phosphorylation and subsequent inhibition of mPTP opening [93] . Prostaglandin E1 (PGE1) has been known to be anti-thrombotic. PGE1 pretreatment significantly improves the cardiological deficits through inactivation of GSK-3β-mPTP signaling pathway [94] . Arachidonyl-2-chloroethylamide (ACEA) protects neurons from damage in ischemic injury through selectively activating cannabinoid receptor 1 (CB1R). ACEA effectively increases the volume and number of mitochondria and promotes the expression of mtTFA, NRF1, and COX IV through inhibitory phosphorylation of GSK-3β, leading to amelioration of mitochondrial function in cerebral ischemia [95] .
GSK-3β has been identified as the modulator of dynamin-related protein 1 (DRP1), which is a GTPase and a key component of the fission machinery in mitochondria responding to intraocular pressure (IOP) elevation. GSK-3β inhibition by LiCl significantly reduces mitochondrial fission and cell death through down-regulation of DRP1 in RGC-5 cells [96] . GSK-3β induces DRP1-Ser616 phosphorylation, causing abnormal mitochondrial alternation in fission. GSK-3β inhibition and DRP1 modulation has been reported to ameliorate mitochondrial impairment, which is responsible for synaptic plasticity deficit in diabetic mice [97] .
Under the condition of oxygen-glucose deprivation/reperfusion, DRP1 physically binds to GSK-3β for form a complex translocating into mitochondria and dysregulation of mPTP opening, leading to mitochondrial dysfunctions. Ginkgolide K, a natural compound isolated from Ginkgo biloba leaves, exhibits neuroprotective effects through significant attenuation of mitochondrial fission and mPTP opening [98] . Exogenous H 2 S exhibits protective roles in IPC-induced cardiomyopathy in the aging process by inhibition of mPTP opening through activating PI3K-Akt-GSK-3β, ERK1/2-GSK-3β, and PKCε-mK ATP signaling pathways [99] . Mitochondrial PKCε antagonizes the effects of PKCδ, which activates GSK-3β and induces mPTP opening under I/R injury. Aldehyde dehydrogenase-2 (ALDH2), a substrate of PKCε, promotes the translocation of PKCε into mitochondria. GSK-3β inhibition ameliorates PKCδ induced ROS-dependent DRP1 phosphorylation and caspase cascade activation [100] .
Conclusion
Stress-induced translocation of GSK-3β into mitochondria indicates to receive signals and challenges from cytoplasm. Accumulative evidence demonstrates that mitochondrial pool of GSK-3β appears to interact with mitochondrial proteins, including PI3K-Akt, HK II, PKCε, components of respiratory chain, and subunits of mPTP. Due to the wide range of substrates, GSK-3β determines the cell fates through modifying the mitochondrial biology. GSK-3β inactivation promotes mitochondrial biogenesis, elevates mitochondrial dynamics, attenuates mitochondrial permeability, and ameliorates mitochondriadependent apoptosis (Fig. 3) . GSK-3β inactivation might become the promising strategy for clinical drugs development. Natural products provide us a great source for exploring the potential therapeutics. However, the versatile effects of GSK-3β are still controversial. More investigation is encouraged.
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